Repeat use of human recombinant bone morphogenetic protein-2 for second level lumbar arthrodesis

Spine

Volumn 36, Issue 3, 2011, Pages 192-196

  Singh, Kern ^a   Dumonski, Mark ^a   Stanley, Tom ^a   Ponnappan, Ravi ^a   Phillips, Frank M ^a  

^a RUSH MEDICAL COLLEGE   (United States)

Author keywords

immune response; posterolateral fusion; rabbit model; repeat; RhBMP 2

Indexed keywords

COLLAGEN ANTIBODY; COLLAGEN SPONGE; INFUSE; RECOMBINANT BONE MORPHOGENETIC PROTEIN 2; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTHRODESIS; ARTICLE; CONTROLLED STUDY; HUMAN; ILIAC CREST; IMMUNE RESPONSE; IMMUNOREACTIVITY; LUMBAR ARTHRODESIS; NONHUMAN; PRIORITY JOURNAL; PROSPECTIVE STUDY; RABBIT; REPEAT PROCEDURE; SEROLOGY; SPINAL HEMATOMA; SPINE DISEASE; SPINE FUSION; SPINE RADIOGRAPHY; TREATMENT OUTCOME;

ANIMALS; ARTHRODESIS; BONE MORPHOGENETIC PROTEIN 2; CATTLE; HUMANS; LUMBAR VERTEBRAE; PROSPECTIVE STUDIES; RABBITS; RECOMBINANT PROTEINS; RETREATMENT; SPINAL FUSION; TRANSFORMING GROWTH FACTOR BETA;

EID: 79551560904     PISSN: 03622436     EISSN: 15281159     Source Type: Journal    
DOI: 10.1097/BRS.0b013e3181cdd396     Document Type: Article

References (21)

1. Suh DY, Boden SD, Louis-Ugbo J, et al. Delivery of recombinant human bone morphogenetic protein-2 using a compression-resistant matrix in posterolateral spine fusion in the rabbit and in the nonhuman primate. Spine 2002;27:353-60.
2. Sandhu HS, Khan SN. Animal models for preclinical assessment of bone morphogenetic proteins in the spine. Spine 2002;27:S32-8.
3. Khurana JS, Ogino S, Shen T, et al. Bone morphogenetic proteins are expressed by both bone-forming and non-bone-forming lesions. Arch Pathol Lab Med 2004;128:1267-9.
4. Fischgrund JS, Mackay M, Herkowitz HN, et al. 1997 Volvo Award winner in clinical studies. Degenerative lumbar spondylolisthesis with spinal stenosis: a prospective, randomized study comparing decompressive laminectomy and arthrodesis with and without spinal instrumentation. Spine 1997;22: 2807-12.
5. Martin GJ Jr, Boden SD, Titus L. Recombinant human bone morphogenetic protein-2 overcomes the inhibitory effect of ketorolac, a nonsteroidal antiinflammatory drug (NSAID), on posterolateral lumbar intertransverse process spine fusion. Spine 1999;24:2188-93.
6. Dimar JR, Glassman SD, Burkus KJ, et al. Clinical outcomes and fusion success at 2 years of single-level instrumented posterolateral fusions with recombinant human bone morphogenetic protein-2/ compression resistant matrix versus iliac crest bone graft. Spine 2006;31:2534-9.
7. Glassman SD, Carreon L, Djurasovic M, et al. Posterolateral lumbar spine fusion with INFUSE bone graft. Spine J 2007;7:44-9.
8. Malter AD, McNeney B, Loeser JD, et al. 5-year reoperation rates after different types of lumbar spine surgery. Spine 1998;23:814-20.
9. Martin GJ Jr, Boden SD, Marone MA, et al. Posterolateral intertransverse process spinal arthrodesis with rhBMP-2 in a nonhuman primate: important lessons learned regarding dose, carrier, and safety. J Spinal Disord 1999;12:179-86.
10. McKay B, Sandhu HS. Use of recombinant human bone morphogenetic protein-2 in spinal fusion applications. Spine 2002;27:S66-85.
11. Sandhu HS. Bone morphogenetic proteins and spinal surgery. Spine 2003;28:S64-73.
12. Sandhu HS, Khan SN. Recombinant human bone morphogenetic protein-2: use in spinal fusion applications. J Bone Joint Surg Am 2003;85(suppl 3):89-95.
13. Schimandle JH, Boden SD, Hutton WC. Experimental spinal fusion with recombinant human bone morphogenetic protein-2. Spine 1995;20:1326-37.
14. Deyo RA, Ciol MA, Cherkin DC, et al. Lumbar spinal fusion. A cohort study of complications, reoperations, and resource use in the Medicare population. Spine 1993;18:1463-70.
15. Singh K, Smucker JD, Ugbo JL, et al. rhBMP-2 enhancement of posterolateral spinal fusion in a rabbit model in the presence of concurrently administered doxorubicin. Spine J 2007;7:326-31.
16. Silcox DH III, Boden SD, Schimandle JH, et al. Reversing the inhibitory effect of nicotine on spinal fusion using an osteoinductive protein extract. Spine 1998;23:291-6.
17. Boden SD, Martin GJ Jr, Morone M, et al. The use of coralline hydroxyapatite with bone marrow, autogenous bone graft, or osteoinductive bone protein extract for posterolateral lumbar spine fusion. Spine 1999;24:320-7.
18. Boden SD, Schimandle JH, Hutton WC. An experimental lumbar intertransverse process spinal fusion model. Radiographic, histologic, and biomechanical healing characteristics. Spine 1995;20:412-20.
19. Erulkar JS, Grauer JN, Patel TC, et al. Flexibility analysis of posterolateral fusions in a New Zealand white rabbit model. Spine 2001;26:1125-30.
20. Kuklo T, Bridwell K, Cillo Y. Is there a clinically detectable response to repeat use of rhBMP-2 in the spine? Paper presented at: Annual meeting of the North American Spine Society; 2007; Austin, TX.
21. Carreon L, Glassman SD, Brock D, et al. Adverse events in patients reexposed to bone morphogenetic protein for spine surgery. Paper presented at: Annual meeting of the North American Spine Society; 2007; Austin, TX.